Clinical Scorecard: Efficacy of Ultrasound-Guided Attenuation Metrics and 2D Shear Wave Elastography in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

At a Glance

Key Highlights

• MASLD is the most common chronic liver disease with ~30% global prevalence and is linked to metabolic dysfunction.
• Liver fibrosis is the main prognostic factor in MASLD, associated with increased mortality risk.
• Ultrasound-guided attenuation parameters (UGAP) and 2D shear wave elastography (2D-SWE) provide noninvasive quantification of hepatic steatosis and fibrosis.

Guideline-Based Recommendations

Diagnosis

• Use liver biopsy as reference standard for fibrosis staging and steatosis grading despite invasiveness.
• Employ ultrasound as primary imaging modality for hepatic steatosis assessment per current guidelines.
• Consider UGAP and 2D-SWE integrated into conventional ultrasound for quantitative assessment of steatosis and fibrosis.

Management

• Monitor hepatic steatosis quantitatively to guide treatment and assess disease progression.
• Exclude other chronic liver disease etiologies and secondary causes of steatosis before MASLD diagnosis.

Monitoring & Follow-up

• Use noninvasive ultrasound-based techniques like UGAP and 2D-SWE for repeated assessments due to biopsy limitations.
• Ensure measurements are performed by trained operators to improve reliability.

Risks

• Liver biopsy carries risks of sampling error and complications, limiting frequent use.
• B-mode ultrasound sensitivity is limited for mild steatosis and operator-dependent.

Patient & Prescribing Data

Adults newly diagnosed with MASLD undergoing initial evaluation without prior treatment

Quantitative ultrasound metrics (UGAP, 2D-SWE) can aid in noninvasive disease monitoring and fibrosis assessment to inform clinical decisions.

Clinical Best Practices

• Perform ultrasound measurements after at least 6 hours fasting with patient supine and right arm elevated.
• Use standardized protocols for UGAP and 2D-SWE acquisition, avoiding vessels and diaphragm in ROI placement.
• Ensure operators have adequate training and experience (minimum 300 prior measurements) for reliable transient elastography and ultrasound assessments.
• Combine UGAP and 2D-SWE in the same ultrasound session to assess both steatosis and fibrosis efficiently.

References

• EASL Clinical Practice Guidelines on NAFLD
• Ultrasound-based Quantification of Hepatic Steatosis
• Transient Elastography and Controlled Attenuation Parameter in Liver Disease